{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Huang YW"],"funding":["Yunnan Science and Technology Talents support plan","Applied Basic Research Key Project of Yunnan"],"pagination":["45-57"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11230660"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["84(1)"],"pubmed_abstract":["<h4>Abstract</h4>Atherosclerosis (AS) is a chronic progressive disease caused by various factors and causes various cerebrovascular and cardiovascular diseases (CVDs). Reducing the plasma levels of low-density lipoprotein cholesterol is the primary goal in preventing and treating AS. Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a crucial role in regulating low-density lipoprotein cholesterol metabolism. Panax notoginseng has potent lipid-reducing effects and protects against CVDs, and its saponins induce vascular dilatation, inhibit thrombus formation, and are used in treating CVDs. However, the anti-AS effect of the secondary metabolite, 20( S )-protopanaxatriol (20( S )-PPT), remains unclear. In this study, the anti-AS effect and molecular mechanism of 20( S )-PPT were inv"],"journal":["Journal of cardiovascular pharmacology"],"pubmed_title":["20( S )-Protopanaxatriol Improves Atherosclerosis by Inhibiting Low-Density Lipoprotein Receptor Degradation in ApoE KO Mice."],"pmcid":["PMC11230660"],"funding_grant_id":["YNWR-QNBJ-2018-083","202301BD070001-029"],"pubmed_authors":["Huang YW","Yang J","Hu D","Sheng J","Luo F","Zhang M","Wang X","Wang L","Meng W"],"additional_accession":[]},"is_claimable":false,"name":"20( S )-Protopanaxatriol Improves Atherosclerosis by Inhibiting Low-Density Lipoprotein Receptor Degradation in ApoE KO Mice.","description":"<h4>Abstract</h4>Atherosclerosis (AS) is a chronic progressive disease caused by various factors and causes various cerebrovascular and cardiovascular diseases (CVDs). Reducing the plasma levels of low-density lipoprotein cholesterol is the primary goal in preventing and treating AS. Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a crucial role in regulating low-density lipoprotein cholesterol metabolism. Panax notoginseng has potent lipid-reducing effects and protects against CVDs, and its saponins induce vascular dilatation, inhibit thrombus formation, and are used in treating CVDs. However, the anti-AS effect of the secondary metabolite, 20( S )-protopanaxatriol (20( S )-PPT), remains unclear. In this study, the anti-AS effect and molecular mechanism of 20( S )-PPT were inv","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jul","modification":"2025-04-04T11:26:05.564Z","creation":"2025-04-04T11:26:05.564Z"},"accession":"S-EPMC11230660","cross_references":{"pubmed":["38922585"],"doi":["10.1097/FJC.0000000000001566"]}}